Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical eye drops for pupil size and accommodative response in adults with myopia
ACTRN12620000433909Phase 2Completed
- Sponsor
- Brien Holden Vision Institute
- Start
- Mar 2020
- Modality
- Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of atropine and caffeine in myopia (2 arms), sponsored by Brien Holden Vision Institute. Primary endpoint: Change in pupillary diameter. Started Mar 2020; status: completed.
02
Drugs
atropinecaffeine
03
Conditions
myopia
Beyond the preview
Go deeper on ACTRN12620000433909.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12620000433909.